Nalaganje...

Physician experiences with sodium-glucose cotransporter (SGLT2) inhibitors, a new class of medications in type 2 diabetes, and adverse effects

AIM: The primary aim of our study is to identify physicians who have witnessed a complication attributed to sodium-glucose cotransporter (SGLT2) inhibitors. The secondary aim is to determine the type, severity, and setting of the event (inpatient versus outpatient). BACKGROUND: Diabetes is an increa...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Prim Health Care Res Dev
Main Authors: Patakfalvi, Laura, Brazeau, Anne-Sophie, Dasgupta, Kaberi
Format: Artigo
Jezik:Inglês
Izdano: Cambridge University Press 2018
Teme:
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6567894/
https://ncbi.nlm.nih.gov/pubmed/30032729
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1017/S1463423618000476
Oznake: Označite
Brez oznak, prvi označite!